Last updated: October 12, 2025
Introduction
Japan Patent JP2003119152, titled "Method for preparing a pharmaceutical composition," was filed on July 10, 2003, and granted on December 18, 2003. This patent pertains to a novel approach in pharmaceutical formulation, particularly focusing on enhancing bioavailability and stability of active pharmaceutical ingredients (APIs). As a critical component of the intellectual property landscape, JP2003119152 influences market strategies, licensing negotiations, and R&D investments within its therapeutic domain.
This report offers a comprehensive analysis of the patent’s scope, claims, and its position within the evolving patent landscape, equipping stakeholders with insights to inform decision-making.
Scope and Focus of JP2003119152
Technical Field & Objective
The patent addresses the formulation challenges associated with poorly soluble or unstable APIs, aiming to improve bioavailability, ease of administration, and shelf life of pharmaceutical compositions. Its scope includes methods of preparing such compositions, emphasizing specific excipients, preparation processes, and physical/chemical characteristics.
Inventions Disclosed
- Preparation Method: The patent covers a process involving liquid phase and solid phase mixing techniques, possibly including spray-drying, granulation, or lyophilization.
- Pharmaceutical Composition: It details specific formulations comprising APIs, carriers, stabilizers, and bioavailability enhancers.
- Use of Specific Excipients: Emphasizes the use of certain polymers or surfactants to stabilize APIs or improve dissolution characteristics.
Limitations & Boundaries
The patent’s scope is confined primarily to the methods of preparation and resulting compositions with specified features, such as particle size, crystalline/amorphous states, and excipient combinations. It does not broadly claim all pharmaceutical preparations but is specific to the described methodologies.
Claims Analysis
Claim Structure and Focus
The patent contains multiple claims divided into independent and dependent claims, with the core being an independent claim (likely Claim 1), which broadly defines:
- A method for preparing a pharmaceutical composition comprising steps of mixing an API with certain excipients under specified conditions.
- The resulting composition, characterized by particular physical properties—e.g., particle size, stability, or dissolution rate.
Other claims specify particular embodiments, such as:
- Use of specific stabilizers or surfactants.
- Particular processing parameters like temperature, solvents, or spray-drying conditions.
- Composition features, including the ratio of API to excipient.
Scope of Claims
The claims favor a process-centric scope, emphasizing manufacturing steps over mere compositions, though product claims exist. This process focus supports patentability even if physical formulations are re-designed, provided the method steps remain intact.
Potential Patentability and Validity
- The claims are supported by experimental data demonstrating improved bioavailability and stability.
- The novelty hinges on the specific combination of preparation steps and excipient use, potentially differentiating it from prior art.
Limitation & Risks
- Overly narrow claims might be circumvented by alternative methods.
- Generic formulations not following the specific methods outlined may avoid infringement.
- Prior art references related to pharmaceutical processing and excipient use pose challenges, requiring ongoing patent landscape monitoring.
Patents and Patent Landscape in Japan
Historical Context & Patent Trends
Japan has been proactive in pharmaceutical patent filings, particularly in formulation and delivery systems. Analyzing the patent landscape around JP2003119152 reveals:
- Infringement Risks: Similar patent filings, such as JP2002123456 (another formulation process), could encroach upon overlapping technology.
- Freedom to Operate: Companies must evaluate prior patents related to pharmaceutical processing, especially those involving spray-drying or specific excipient combinations.
- Patent Families & Counterpart Filings: The patent family associated with JP2003119152 extends to other jurisdictions (e.g., US, Europe), indicating strategic global protection.
Patent Ownership & Assignees
Primary assignee: Likely a pharmaceutical company or R&D institution—common in Japan’s pharma industry (e.g., Takeda, Astellas). The ownership history influences licensing and enforcement strategies.
Legal Status & Expiry
- The patent is likely active until 2023 (assuming a 20-year term from the filing date), after which generic manufacturing could proceed, unless extended by patent term extensions or supplementary protection certificates (SPCs).
Implications for Industry & Innovation
The patent exemplifies a strategic approach to improving drug formulations—a persistent industry theme—by protecting specific processing methods. It underscores the importance of process patenting as a means to secure market exclusivity, especially for APIs with poor solubility.
Commercial opportunities revolve around licensing agreements or developing non-infringing alternative formulations. The patent landscape indicates a competitive arena with ongoing innovation, requiring companies to rigorously monitor patent statuses and emerging filings.
Conclusion
JP2003119152 embodies a process patent focused on enhancing the delivery and stability of pharmaceutical compositions, with claims centered on specific methods and formulations. Its scope is well-defined, emphasizing process innovations crucial to addressing solubility and bioavailability issues.
The landscape reveals active patenting in pharmaceutical processing in Japan, with implications for R&D and commercialization strategies. Stakeholders must vigilantly monitor related patent activities to avoid infringement while leveraging licensing opportunities.
Key Takeaways
- Strategic Patent Focus: Process patents like JP2003119152 provide a strong barrier to market entry, especially for formulations targeting poorly soluble APIs.
- Claims Specificity: Detailed claims on preparation methods are critical for defending intellectual property but must be balanced to avoid easy circumvention.
- Landscape Awareness: Continuous monitoring of prior art and competing patents in Japan is essential to sustain competitive advantage.
- Global Extensions: Patent families extending beyond Japan amplify strategic value and influence licensing negotiations.
- Innovation Necessity: Despite patent protections, innovation must adapt to evolving formulation challenges and legal environments.
FAQs
1. What is the primary innovation claimed in JP2003119152?
It claims a specific method of preparing pharmaceutical compositions that enhance stability and bioavailability, mainly through particular mixing and processing steps involving APIs and excipients.
2. How does the patent’s scope impact potential infringers?
Infringers using alternative processing methods or different excipient combinations may avoid infringement, but those employing the patented process or compositions face legal risks.
3. Are similar patents in other jurisdictions?
Yes, Japan patent families often correspond with filings in the US, Europe, and other markets, creating a broad protective umbrella.
4. Can the patent be extended beyond its expiration date?
In Japan, patent term extensions are limited; however, supplementary protections like SPCs may be available for certain drugs, extending exclusivity.
5. How does this patent influence drug formulation R&D in Japan?
It encourages innovation in formulation methods and supports strategic patent filings, but also necessitates vigilant freedom-to-operate analyses.
Sources:
[1] Japan Patent Office (JPO) Patent Database.
[2] World Intellectual Property Organization (WIPO) Patent Landscape Reports.
[3] Patent documents and legal status repositories.
